Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Cancer Supportive Care Products Market Expected to Grow Between 2025 And 2029?

The market for cancer supportive care products has seen substantial growth in the past few years. The market size is projected to rise from $21.56 billion in 2024 to $22.65 billion in 2025, with a compound annual growth rate (CAGR) of 5.1%. The growth observed during the historical period is linked to an increase in cancer cases, enhanced awareness and education, improvements in healthcare infrastructure, a rise in the aging population, heightened awareness, and early detection.

What Growth Rate Is Anticipated for the Cancer Supportive Care Products Market in the Coming Years?

In the upcoming years, the market size for cancer supportive care products is anticipated to experience constant growth, with a projection to reach $27.32 billion by 2029, growing at a compound annual growth rate (CAGR) of 4.8%. This growth during the estimated period could be due to an increase in cancer occurrences, the evolution of patient-focused strategies, ascending investment in cancer studies, a heightened emphasis on personalized treatment, and improved cancer survival rates. Key trends during the estimated period encompass technology enhancements, sophisticated drug delivery methods, novel drug formulae, individualized care, along with the invention of eco-friendly products.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18529&type=smp

Who Are the Leading Companies in the Cancer Supportive Care Products Market?

Major companies operating in the cancer supportive care products market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Becton Dickinson and Company, Teva Pharmaceutical Industries Limited, Baxter International Inc., Daiichi Sankyo Company Limited, Agilent Technologies Inc., Hologic Inc., Illumina Inc., Kyowa Hakko Kirin Co. Ltd., QIAGEN N.V., Exelixis Inc., Fagron Group B.V., Tessa Therapeutics Pte Ltd., Mirati Therapeutics Inc., APR Applied Pharma Science Research S.A., Acacia Pharma Ltd., Arquer Diagnostics Ltd.

What Are the Key Drivers of the Cancer Supportive Care Products Market?

The surge in cancer cases is anticipated to drive the cancer supportive care products market’s expansion in the future. This rise is attributed to the aging population, which results in an increased chance of cancer due to cellular alterations and prolonged exposure to risk elements. Factors like smoking, unhealthy eating, physical inactivity, and excessive drinking also significantly amplify the risk of cancer. Cancer supportive care products play a crucial role in symptom management, enhancing life quality, and assisting patients during treatment. This addresses the escalating necessity stemming from the rising prevalence of cancer. For example, the American Cancer Society – a US non-profit organization on a mission to eradicate cancer – projected in January 2024 that the number of oral cavity and pharynx cancer cases would reach 58,450, marking a 7.2% growth from the 54,540 cases in 2023. Hence, the increasing occurrence of cancer will fuel the expansion of the cancer supportive care products market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=18529&type=smp

What Are the Key Market Segments in the Cancer Supportive Care Products Industry?

The cancer supportive care products market covered in this report is segmented –

1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs, Anti-Infective, Anti-Emetics, Monoclonal Antibodies, Erythropoietin Stimulating Agents, Opioid Analgesics, Bisphosphonates, Granulocyte Colony Stimulating Factor

2) By Indication: Lung Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Leukemia, Ovary Cancer, Melanoma Cancer, Other Indications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Compounding Pharmacies

Subsegments

1) By Nonsteroidal Anti-Inflammatory Drugs (Nsaids): Ibuprofen, Aspirin, Naproxen

2) By Anti-Infective: Antibiotics, Antifungal Drugs, Antiviral Drugs

3) By Anti-Emetics: 5-Ht3 Antagonists (Ondansetron), Nk1 Antagonists (Aprepitant), Corticosteroids (Dexamethasone)

4) By Monoclonal Antibodies: Rituximab, Trastuzumab, Bevacizumab

5) By Erythropoietin Stimulating Agents: Epoetin Alfa, Darbepoetin Alfa

6) By Opioid Analgesics: Morphine, Fentanyl, Oxycodone

7) By Bisphosphonates: Zoledronic Acid, Pamidronate, Ibandronate

8) By Granulocyte Colony Stimulating Factor: Filgrastim, Pegfilgrastim

What Are the Latest Trends in the Cancer Supportive Care Products Market?

Key players in the cancer support care product industry are concentrating on the progression of cancer therapies like targeted radioligand therapy (RLT), with the intent of increasing the efficiency of treatment, decreasing adverse effects, and enhancing patient outcomes. This specific therapy utilizes radiolabeled molecules, which directly bind to cancer cell markers, delivering local radiation and selectively obliterating cancer cells but preserving healthy tissue. For instance, in May 2022, Swiss pharmaceutical corporation Novartis AG obtained approval from the US Food and Drug Administration (FDA) for the introduction of Pluvicto (lutetium Lu 177 vipivotide tetraxetan). This drug is intended for the treatment of adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) that has progressed despite previous treatments. Pluvicto is the first FDA-approved RLT for qualified mCRPC patients, fusing a targeting ligand with a therapeutic radioisotope. Furthermore, FDA has also given the green light for Locametz (gallium Ga 68 gozetotide injection), used in PET scans to identify PSMA-positive lesions, thereby assisting in pinpointing the location of cancer spread and determining the patient’s suitability for Pluvicto treatment.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cancer-supportive-care-products-global-market-report

What Are the Key Regional Markets in the Cancer Supportive Care Products Industry?

North America was the largest region in the cancer supportive care products market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer supportive care products market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18529

This Report Delivers Insight On:

1. How big is the cancer supportive care products market, and how is it changing globally?

2. Who are the major companies in the cancer supportive care products market, and how are they performing?

3. What are the key opportunities and risks in the cancer supportive care products market right now?

4. Which products or customer segments are growing the most in the cancer supportive care products market?

5. What factors are helping or slowing down the growth of the cancer supportive care products market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model